Chinese herb injections for viral pneumonia: an overview of systematic reviews_Chinese Journal of Evidence-Based Medicine

Authors：

YANG Kelu ¹ , JIN Xinyao ² , LIU Ming ³ , GAO Ya ³ ,  TIAN Jinhui ^1,3

1. Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou 730000, P.R.China;
2. Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R.China;
3. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P.R.China;

Corresponding author：

TIAN Jinhui, Email: tianjh@lzu.edu.cn

Keywords：

Chinese herb injections; Viral pneumonia; Overview of systematic review; AMSTAR 2; GRADE

DOI：

10.7507/1672-2531.202003111

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To overview the systematic reviews of traditional Chinese herb injections for viral pneumonia.Methods CNKI, CBM, WanFang Data, VIP, PubMed, Web of Science, The Cochrane Library and EMbase databases were electronically searched to collect systematic reviews (SRs) of traditional Chinese herb injections for viral pneumonia from inception to March 2020. Two reviewers independently screened literature and extracted data. Then, AMSTAR 2 was used to assess the methodological quality and GRADE was used to grade the outcome indicators of included SRs.Results A total of 10 SRs were included, containing six Chinese herb injections (Xiyanping injection, Yanhuning injection, Tanreqing injection, Reduning injection, Shuanghuanglian injection, and Chuanhuning injection). Five items of AMSTAR 2 were reported well, and two items were not reported in any of the included SRs, and the quality was unsatisfactory. The efficacy of Chinese herb injection was superior than that of western medicine in many outcome indicators, such as antipyretic time, the pulmonary rales disappearing time, and the total clinical efficiency. The quality of evidence ranged from medium to very low.Conclusions Current evidence shows that the quality of SRs of Chinese herb injections for viral pneumonia requires improvement, and most of the results show that Chinese herb injections are more effective than western medicines.

Citation： YANG Kelu, JIN Xinyao, LIU Ming, GAO Ya, TIAN Jinhui. Chinese herb injections for viral pneumonia: an overview of systematic reviews. Chinese Journal of Evidence-Based Medicine, 2020, 20(11): 1326-1333. doi: 10.7507/1672-2531.202003111 Copy

1.	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2.	国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第六版)的通知, 2020-02-25. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml?from=timeline.
3.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
4.	周涛, 刘权辉, 杨紫陌, 等. 新型冠状病毒肺炎基本再生数的初步预测. 中国循证医学杂志, 2020, 20(3): 359-364.
5.	世界卫生组织. 关于 2019 新型冠状病毒疫情的《国际卫生条例(2005)》突发事件委员会第二次会议的声明, 2020-02-25. Available at: https://www.who.int/zh/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
6.	世界卫生组织. 世卫组织总干事在 2020 年 2 月 24 日举行的 2019 冠状病毒病疫情媒体通报会上的讲话, 2020-02-25. Available at: https://www.who.int/zh/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-24-february-2020.
7.	Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, 75(7): 1730-1741.
8.	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
9.	陈永, 杨泽民, 陈吉生, 等. 新型冠状病毒肺炎药物临床试验现状及研究进展. 今日药学, 2020, 30(3): 160-163.
10.	赵晔, 刘丹璐, 李金龙, 等. 9 种中药注射剂联合多西他赛和顺铂/卡铂治疗非小细胞肺癌的网状 Meta 分析. 中国药物评价, 2014, 31(5): 295-299.
11.	王辉, 金鑫瑶, 庞博, 等. 中医药干预新型冠状病毒肺炎临床研究方案分. 中国中药杂志, 2020, 45(6): 1232-1241.
12.	邵仲柏, 朱月霞, 刘书豪, 等. 临床使用治疗新型冠状病毒肺炎中药复方中高频数中药抗病毒研究概述. 中草药, 2020, 51(5): 1153-1158.
13.	刘雅莉, 袁金秋, 杨克虎, 等. 系统评价再评价的制作方法简介及相关资料分析. 中国循证儿科杂志, 2011, 6(1): 58-64.
14.	田金徽. 系统评价再评价撰写注意事项. 中国药物评价, 2019, 36(1): 1-4.
15.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
16.	Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454): 1490.
17.	Guyatt GH, Oxman AD, Vist GE, 等. GRADE: 证据质量和推荐强度分级的共识. 中国循证医学杂志, 2009, 9(1): 8-11.
18.	马明星, 王雪峰, 张秀英, 等. 喜炎平注射液治疗儿童呼吸道合胞病毒肺炎有效性及安全性的 Meta 分析. 中国中西医结合儿科学, 2019, 11(4): 301-307.
19.	齐蕊涵, 方赛男, 李得民, 等. 喜炎平注射液治疗成人病毒性肺炎的系统评价和 Meta 分析. 现代中医临床, 2018, 25(3): 29-33.
20.	谢辉辉, 祁波, 杜丽娜, 等. 喜炎平注射液治疗儿童病毒性肺炎疗效及安全性的 Meta 分析. 时珍国医国药, 2014, 25(10): 2546-2549.
21.	Sun SG. Xiyanping injection in treatment of viral pneumonia in children: a meta-analysis of random control trials. Chin Herb Med, 2015, (2): 173-178.
22.	韩燕鸿, 揭珂, 张荷. 炎琥宁注射液治疗小儿病毒性肺炎疗效和安全性的系统评价. 中国实验方剂学杂志, 2016, 22(9): 203-207.
23.	陈昭燕, 占美, 田方圆, 等. 穿琥宁注射液治疗病毒性肺炎有效性与安全性 Meta 分析. 中国药业, 2018, 27(2): 38-42.
24.	祁波, 王明明. 痰热清注射液治疗病毒性肺炎的 Meta 分析. 浙江中医药大学学报, 2013, (8): 979-982.
25.	胡廷雪. 热毒宁注射液治疗小儿病毒性肺炎的 Meta 分析. 长江大学学报, 2013, 10(18): 87-90.
26.	孙亚磊, 袁斌. 四种中药注射液治疗病毒性肺炎的疗效分析: 一项网状 Meta 分析研究. 中华中医药学刊, 2020, 38(7): 113-120.
27.	王博龙, 李跃文, 邹盛勤. 清热解毒类中药注射液治疗小儿病毒性肺炎的网状 Meta 分析. 中成药, 2018, 40(12): 2644-2649.
28.	杨克虎, 刘雅莉, 袁金秋, 等. 发展和完善中的系统评价再评价. 中国循证儿科杂志, 2011, 6(1): 54-57.
29.	Bougioukas KI, Bouras E, Apostolidou-Kiouti F, et al. Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol, 2019, 106: 70-79.
30.	Pollock A, Campbell P, Brunton G, et al. Selecting and implementing overview methods: implications from five exemplar overviews. Syst Rev, 2017, 6(1): 145.
31.	McKenzie JE, Brennan SE. Overviews of systematic reviews: great promise, greater challenge. Syst Rev, 2017, 6(1): 185.
32.	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
33.	王志飞, 张洪春, 谢雁鸣, 等. 喜炎平注射液治疗呼吸系统感染性疾病临床应用专家共识(成人版). 中国中药杂志, 2019, 44(24): 5282-5286.
34.	张玲, 马万强, 梅波, 等. 痰热清注射液治疗甲型流感的 Meta 分析. 中成药, 2019, 41(6): 1288-1293.
35.	党娇娇, 吕健, 孙梦华, 等. 热毒宁注射液治疗急性气管-支气管炎的系统评价与 Meta 分析. 中国中药杂志, 2019, 44(24): 5294-5302.
36.	余莹, 程健, 于唱, 等. 双黄连雾化吸入治疗慢性咽炎疗效及安全性的 Meta 分析. 时珍国医国药, 2019, 30(6): 1506-1510.

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2. 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第六版)的通知, 2020-02-25. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml?from=timeline.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
4. 周涛, 刘权辉, 杨紫陌, 等. 新型冠状病毒肺炎基本再生数的初步预测. 中国循证医学杂志, 2020, 20(3): 359-364.
5. 世界卫生组织. 关于 2019 新型冠状病毒疫情的《国际卫生条例(2005)》突发事件委员会第二次会议的声明, 2020-02-25. Available at: https://www.who.int/zh/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
6. 世界卫生组织. 世卫组织总干事在 2020 年 2 月 24 日举行的 2019 冠状病毒病疫情媒体通报会上的讲话, 2020-02-25. Available at: https://www.who.int/zh/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-24-february-2020.
7. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, 75(7): 1730-1741.
8. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
9. 陈永, 杨泽民, 陈吉生, 等. 新型冠状病毒肺炎药物临床试验现状及研究进展. 今日药学, 2020, 30(3): 160-163.
10. 赵晔, 刘丹璐, 李金龙, 等. 9 种中药注射剂联合多西他赛和顺铂/卡铂治疗非小细胞肺癌的网状 Meta 分析. 中国药物评价, 2014, 31(5): 295-299.
11. 王辉, 金鑫瑶, 庞博, 等. 中医药干预新型冠状病毒肺炎临床研究方案分. 中国中药杂志, 2020, 45(6): 1232-1241.
12. 邵仲柏, 朱月霞, 刘书豪, 等. 临床使用治疗新型冠状病毒肺炎中药复方中高频数中药抗病毒研究概述. 中草药, 2020, 51(5): 1153-1158.
13. 刘雅莉, 袁金秋, 杨克虎, 等. 系统评价再评价的制作方法简介及相关资料分析. 中国循证儿科杂志, 2011, 6(1): 58-64.
14. 田金徽. 系统评价再评价撰写注意事项. 中国药物评价, 2019, 36(1): 1-4.
15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
16. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454): 1490.
17. Guyatt GH, Oxman AD, Vist GE, 等. GRADE: 证据质量和推荐强度分级的共识. 中国循证医学杂志, 2009, 9(1): 8-11.
18. 马明星, 王雪峰, 张秀英, 等. 喜炎平注射液治疗儿童呼吸道合胞病毒肺炎有效性及安全性的 Meta 分析. 中国中西医结合儿科学, 2019, 11(4): 301-307.
19. 齐蕊涵, 方赛男, 李得民, 等. 喜炎平注射液治疗成人病毒性肺炎的系统评价和 Meta 分析. 现代中医临床, 2018, 25(3): 29-33.
20. 谢辉辉, 祁波, 杜丽娜, 等. 喜炎平注射液治疗儿童病毒性肺炎疗效及安全性的 Meta 分析. 时珍国医国药, 2014, 25(10): 2546-2549.
21. Sun SG. Xiyanping injection in treatment of viral pneumonia in children: a meta-analysis of random control trials. Chin Herb Med, 2015, (2): 173-178.
22. 韩燕鸿, 揭珂, 张荷. 炎琥宁注射液治疗小儿病毒性肺炎疗效和安全性的系统评价. 中国实验方剂学杂志, 2016, 22(9): 203-207.
23. 陈昭燕, 占美, 田方圆, 等. 穿琥宁注射液治疗病毒性肺炎有效性与安全性 Meta 分析. 中国药业, 2018, 27(2): 38-42.
24. 祁波, 王明明. 痰热清注射液治疗病毒性肺炎的 Meta 分析. 浙江中医药大学学报, 2013, (8): 979-982.
25. 胡廷雪. 热毒宁注射液治疗小儿病毒性肺炎的 Meta 分析. 长江大学学报, 2013, 10(18): 87-90.
26. 孙亚磊, 袁斌. 四种中药注射液治疗病毒性肺炎的疗效分析: 一项网状 Meta 分析研究. 中华中医药学刊, 2020, 38(7): 113-120.
27. 王博龙, 李跃文, 邹盛勤. 清热解毒类中药注射液治疗小儿病毒性肺炎的网状 Meta 分析. 中成药, 2018, 40(12): 2644-2649.
28. 杨克虎, 刘雅莉, 袁金秋, 等. 发展和完善中的系统评价再评价. 中国循证儿科杂志, 2011, 6(1): 54-57.
29. Bougioukas KI, Bouras E, Apostolidou-Kiouti F, et al. Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol, 2019, 106: 70-79.
30. Pollock A, Campbell P, Brunton G, et al. Selecting and implementing overview methods: implications from five exemplar overviews. Syst Rev, 2017, 6(1): 145.
31. McKenzie JE, Brennan SE. Overviews of systematic reviews: great promise, greater challenge. Syst Rev, 2017, 6(1): 185.
32. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
33. 王志飞, 张洪春, 谢雁鸣, 等. 喜炎平注射液治疗呼吸系统感染性疾病临床应用专家共识(成人版). 中国中药杂志, 2019, 44(24): 5282-5286.
34. 张玲, 马万强, 梅波, 等. 痰热清注射液治疗甲型流感的 Meta 分析. 中成药, 2019, 41(6): 1288-1293.
35. 党娇娇, 吕健, 孙梦华, 等. 热毒宁注射液治疗急性气管-支气管炎的系统评价与 Meta 分析. 中国中药杂志, 2019, 44(24): 5294-5302.
36. 余莹, 程健, 于唱, 等. 双黄连雾化吸入治疗慢性咽炎疗效及安全性的 Meta 分析. 时珍国医国药, 2019, 30(6): 1506-1510.

Previous Article
Guidelines concerning pharmacological intervention for migraine in adults: a systematic review
Next Article
Measurement methods of dyspnea in clinical trials of acute heart failure

Chinese Journal of Evidence-Based Medicine

Chinese herb injections for viral pneumonia: an overview of systematic reviews

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content